SEC Form 4 · accession 0001209191-16-097387
MERRIMACK PHARMACEUTICALS INC · MACK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yasir B. Al-Wakeel
Officer — CFO and Head of Corp Dev
Period of report
Feb 8, 2016
Accepted (ET)
Feb 10, 2016 · 5:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001274792
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $5.42 | Feb 8, 2016 | A | 105,000 | A | — | Feb 7, 2026 | Common Stock | 105,000 | 105,000 | D |
Explanation of responses
- F1This option vests as to 1/12th of the total number of shares on 5/8/16 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 2/8/19.